BLIFFYBliffy Price

On October 9, Moderna will officially be included in the Nasdaq 100 Index before the US stock market opens at 21:30 Beijing time, replacing Warner Bros. Discovery. This adjustment was announced on October 1. From the market close on October 1, prior to the announcement, to the latest close on October 8, MRNA's stock price rose from $188.94 to $197, an increase of approximately 4.27%. Moderna is a US biotechnology company that develops vaccines and drugs using mRNA technology, with research covering infectious diseases, cancer, and rare diseases. In addition to its vaccine business, the company announced positive results from a Phase III trial of its personalized mRNA cancer therapy in collaboration with Merck in August, achieving the primary endpoint of disease-free survival in adjuvant melanoma treatment, which has been a major catalyst for its stock price. Recently, a suspected case of pneumonic plague in Russia has also drawn attention to vaccine stocks, with Moderna's shares rising approximately 6.95% on October 5. However, as of the latest public information, the pathogen involved in the incident has not been confirmed by the WHO, and Russian officials stated that no plague was found in contact testing; the European Centre for Disease Prevention and Control also indicated that there is currently no evidence of sustained human-to-human transmission. According to TradingBeats monitoring, MRNA's on-chain contract is priced at $196.45, up about 0.56% in the last 24 hours; the open interest is approximately 15,600 contracts, with a nominal value of about $3.059 million; 24-hour trading volume is about 43,500 contracts, with a trading value of about $8.521 million. The two largest long positions combined hold about $448,500 in long positions, with an unrealized profit of about $61,500: - Largest long: approximately $242,500 in long positions. Holding 1,233.05 contracts with 3x leverage, average price $175.78, unrealized profit about $25,800, return approximately 35.7%, liquidation price $124.15 (0x9a37…). - Second largest long: approximately $205,900 in long positions. Holding 1,046.98 contracts with 10x leverage, average price $162.58, unrealized profit about $35,700, return approximately 209.8%, liquidation price $154.69 (0x599d…). The second long has set a market order to trigger a take-profit at $350, covering all existing positions, approximately 77.9% higher than the current price.

On October 9, according to Farside data, the U.S. Ethereum spot ETF experienced a net outflow of $72.5 million yesterday, marking the eighth consecutive trading day of net outflows.

The recent fluctuations in Bitcoin (BTC) have raised questions about whether the pullback has reached its conclusion. In just one night, over 100 million new orders have been placed, which could provide insights into potential bottom-fishing opportunities for investors.